What’s Next? Five Things To Look Out For In August
Sven Dethlefs Replaces Outgoing Teva North America Head Brendan O’Grady
In the month ahead, Teva will see a key management change, Polpharma is set to wrap up a landmark Phase III biosimilar study and financial results for all manner of industry participants will continue to trickle out.
You may also be interested in...
Teva is keeping a keen eye out for opportunities like its US biosimilars agreement with Alvotech and more recent deal with Bioeq for biosimilar Lucentis as it attempts to maintain revenues in the coming years, following a cut to full-year sales guidance for 2021.
Sandoz enjoyed both top- and bottom-line growth in the second quarter, as the Novartis company rebounded from a challenging Q1 and explained how it would reach its financial targets in the longer term.
Teva has announced a major management reshuffle that will see North America commercial vice-president Brendan O’Grady leave the company for a new role outside the pharmaceutical industry. Revealing his replacement, Teva also unveiled further changes.